Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Adults with obesity and type 2 diabetes receiving once-weekly combination cagrilintide 2.4 mg and semaglutide 2.4 mg lost ...
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Novo Nordisk (NVO) announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE program. REDEFINE 2 is a 68-week efficacy ...
The Wegovy successor was able to meet its primary endpoint with a 15.7% weight loss among those dosed with the combination ...
Zacks.com on MSN2d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk stock slumps as the 15.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in the second ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback